We use cookies to improve your experience and to help us understand how our site is used. You can find out more about your options on our
Cookies page.
About Cookies
Most websites these days use cookies to store and retrieve information. Some of this information might be about you,
your preferences or your device and is mostly used to help the website work in the way you expect.
This information doesn’t usually directly identify you but can give you a more personalized experience.
We will never sell any of your personally identifiable information, whether gathered using a cookie or otherwise.
We respect your right to privacy, so you can choose whether or not some cookies are enabled on our website.
However, disabling some cookies can impact your experience and the services we are able to offer. For more information see our Cookie settings and Privacy Policy.
Essential Cookies (Required)
These cookies are essential for the website to work properly and can’t be turned off.
They don’t collect personal information.
We also use them to understand how the site is used.
You can choose to block these cookies in your browser, but parts of the site might not work as expected.
Analytics Cookies (Optional)
These cookies help us improve our website and keep content relevant.
We use third-party tools to analyse information gathered by cookies and understand how visitors use our website.
We only use information gathered by cookies internally. See our Privacy Policy.
You can turn these cookies off by clicking "Reject optional cookies", but parts of the site might not work as expected.
Below is a text only representation of the Patient Information Leaflet (ePIL).
The text only version may be available in large print, Braille or audio CD.
For further information call emc accessibility on
0800 198 5000.
The product code(s) for this leaflet is: PLGB 41042/0088.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor, pharmacist, or nurse.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
1. What AQUIPTA is and what it is used for 2. What you need to know before you take AQUIPTA 3. How to take AQUIPTA 4. Possible side effects 5. How to store AQUIPTA 6. Contents of the pack and other information
1. What AQUIPTA is and what it is used for
AQUIPTA contains the active substance atogepant.
How AQUIPTA works
AQUIPTA works by blocking the activity of the calcitonin gene-related peptide (CGRP) molecule which has been linked to migraine. This reduction in CGRP’s activity reduces migraine attacks.
What AQUIPTA is used for
AQUIPTA is used in adult patients to:
treat an active migraine attack
prevent migraine in those who have at least 4 migraine days per month
2. What you need to know before you take AQUIPTA
Do not take AQUIPTA
If you are allergic to atogepant or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking AQUIPTA, especially if you:
have liver problems
have kidney problems
Allergic reactions
Stop taking AQUIPTA and tell your doctor immediately if you experience any symptoms of an allergic reaction such as:
difficulty breathing
swelling of the face
rash, itching, or hives
Some of these symptoms can occur several days after you take AQUIPTA.
Children and adolescents
Do not give this medicine to children or adolescents (under 18 years old) because the use of AQUIPTA has not been studied in this age group.
Other medicines and AQUIPTA
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines may increase the risk of getting side effects.
The following is a list of examples of medicines that may require your doctor to lower the dose of AQUIPTA:
ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, rifampicin (medicines used to treat fungal or bacterial infections)
atazanavir, indinavir, nelfinavir, ritonavir, saquinavir, tipranavir (medicines used to treat HIV)
ciclosporin (medicine that affects your immune system)
telmisartan (medicine used to treat high blood pressure)
If any of the above apply to you or you are not sure, talk to your doctor or pharmacist before taking AQUIPTA.
Pregnancy, breast-feeding and fertility
AQUIPTA is not recommended during pregnancy.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
Driving and using machines
AQUIPTA may make you feel sleepy. Do not drive or use machines if you are affected.
AQUIPTA contains sodium
This medicine contains 31.5 mg sodium (main component of cooking/table salt) in each 60 mg tablet. This is equivalent to 1.6% of the recommended maximum daily dietary intake of sodium for an adult.
This medicine contains less than 1 mmol sodium (23 mg) per 10 mg tablet, that is to say essentially ‘sodium-free’.
3. How to take AQUIPTA
Always take this medicine exactly as your doctor has told you. Speak to your doctor or pharmacist if you are not sure.
How much to take
The maximum dose per day is 60 mg.
For treatment of a migraine attack as needed, the recommended dose is 60 mg.
For prevention of migraine, the recommended dose is 60 mg once a day.
Your doctor may tell you to take a lower dose if you are taking other medicines (listed in section 2) or if you have severe kidney problems. Speak to your doctor if you are undergoing dialysis.
How to take
AQUIPTA may be taken with or without food.
If you take more AQUIPTA than you should
If you have used more AQUIPTA than you should, tell your doctor.
If you forget to take AQUIPTA
If you take AQUIPTA for the prevention of migraine and forget to take it:
A missed dose should be taken straight away. If it is close to your scheduled next dose, do not take a double dose to make up for a forgotten tablet.
If you stop taking AQUIPTA
If you take AQUIPTA for the prevention of migraine, do not stop using it without talking to your doctor first. Your symptoms may return if you stop the treatment.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Stop taking AQUIPTA and contact your doctor immediately if you have any of the following symptoms, which may be part of a serious allergic reaction:
difficulty breathing
swelling of the face
rash, itching, or hives
Other side effects
Tell your doctor or nurse if you notice any of the following side effects:
Common (may affect up to 1 in 10 people)
feeling sick (nausea)
constipation
tiredness (fatigue) or sleepiness (somnolence)
decreased appetite
weight loss
Uncommon (may affect up to 1 in 100 people)
increased levels of liver enzymes
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store AQUIPTA
Keep this medicine out of the sight and reach of children.
This medicinal product does not require any special storage conditions.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6. Contents of the pack and other information
What AQUIPTA contains
The active substance is atogepant.
Each tablet contains either 10 mg or 60 mg of atogepant.
The other ingredients are: Polyvinylpyrrolidone/Vinyl acetate copolymer, vitamin E polyethylene glycol succinate, mannitol, microcrystalline cellulose, sodium chloride, croscarmellose sodium, colloidal silicon dioxide and sodium stearyl fumarate.
What AQUIPTA looks like and contents of the pack
AQUIPTA 10 mg tablets
AQUIPTA 10 mg tablet is a white to off-white, round biconvex tablet debossed with “A” and “10” on one side.
AQUIPTA 60 mg tablets
AQUIPTA 60 mg tablet is a white to off-white, oval biconvex tablet debossed with “A60” on one side.
For packs of 2 tablets, each blister contains 2 tablets.
For packs of 7, 28 or 98 tablets, each blister contains 7 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
AbbVie Ltd Maidenhead SL6 4UB UK
Tel: +44 (0)1628 561090
Manufacturer
AbbVie S.r.l S.R. 148 Pontina Km 52 Snc Campoverde di Aprilia Latina 04011 Italy
This leaflet was last revised in November 2025.
To listen to or request a copy of this leaflet in Braille, large print or audio, please contact the Marketing Authorisation Holder.
AbbVie Ltd
Address
AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4UB, UK